自20世纪40年代初Huggins等率先证实内分泌疗法可有效减缓前列腺癌进展,至今前列腺癌的内分泌治疗经历了70多年的沉淀与积累,从缓解转移症状的辅助治疗策略发展为目前公认的晚期前列腺癌一线治疗方案.近年来,多项大规模临床试验的显著成果将新型内分泌治疗药物阿比特龙与恩杂鲁胺引入晚期前列腺癌的治疗蓝图,极大地推动了前列腺癌内分泌治疗的临床研究与应用.笔者通过对前列腺癌内分泌治疗的现状分析,浅谈其未来发展趋势,以期为临床治疗带来新的启发与思考.%It has been more than 70 years since Huggins and Hodges demonstrated the beneficial effects of hormonal therapy on prostate cancer .Androgen-suppressing strategies have formed the cornerstone of management of advanced prostate cancer as the first line of the treatment.Currently,abiraterone and enzalutamide,two of the newest drugs,have expanded treatment options for castration -resist-ant prostate cancer with promising clinical outcomes .Herein,we would like to briefly review the status in quo of hormonal therapy as well as discuss the prospective trends for the purpose of maximizing its clinical effects for prostate cancer .
展开▼
